CCO Infectious Disease Podcast

Key Studies Influencing My Practice Following IAS 2021—Audio Recap

Episode Summary

Listen to expert insights from Babafemi Taiwo, MBBS, on updates from IAS 2021, including new data on COVID-19 and HIV, 2-drug ART, long-acting injectable ART, investigational agents, and new therapies for multidrug-resistant tuberculosis.

Episode Notes

In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:

• WHO Global Clinical Platform: COVID-19 outcomes in PWH
• 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)
• Investigational antiretroviral use
  • CAB LA + RPV LA in treatment-naive PWH (FLAIR)
• Investigational antiretroviral agents
  • LEN (CAPELLA, CALIBRATE)
  • ISL (P011, P016)
• Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)

Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP.; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at: 
https://bit.ly/3syWD5T

Link to full program: 
https://bit.ly/3z8SBnC